Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902897 | 1.00 | LMNA (0.31) | LMNASMN1; SMN2POLBALDH1A1CYP1A2 | |
| SCHEMBL9903354 | 0.81 | SMN1; SMN2 (0.33) | LMNASMN1; SMN2ALDH1A1CYP1A2HPGD | |
| SCHEMBL9903873 | 0.79 | SMN1; SMN2 (0.32) | SMN1; SMN2HPGD | |
| SCHEMBL9903405 | 0.78 | GPR35 (0.35) | SMN1; SMN2 | |
| SCHEMBL9902728 | 0.78 | GLRA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL9903657 | 0.78 | GLRA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL9903307 | 0.78 | GPR35 (0.35) | SMN1; SMN2 | |
| SCHEMBL9903582 | 0.76 | SMN1; SMN2 (0.30) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9903396 | 0.73 | — | — | |
| SCHEMBL9903595 | 0.72 | GRM2 (0.38) | SMN1; SMN2POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916549-B2 | Thienooxazepine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2463290-B1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-2463290-A1 | THIENOOXAZEPINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | HTR2C, HTR2B, HTR2A | LMNA 3542/4885SMN1; SMN2 3302/4885POLB 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.